CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial Ambulatory Electrocardiogram Monitoring in Patients Undergoing Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review Infective Endocarditis After Transcatheter Aortic Valve Replacement Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin? Impact of Percutaneous Revascularization on Exercise Hemodynamics in Patients With Stable Coronary Disease Decline in Left Ventricular Ejection Fraction During Follow-Up in Patients With Severe Aortic Stenosis

Clinical Trial2014 Jan 21;129(3):304-12.

JOURNAL:Circulation. Article Link

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

Lee CW, Ahn JM, Park SJ et al. Keywords: dAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

FULL TEXT PDF